Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Non-Current Liabilities: 2020-2025

Historic Total Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $654.3 million.

  • Apellis Pharmaceuticals' Total Non-Current Liabilities fell 0.09% to $654.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654.3 million, marking a year-over-year decrease of 0.09%. This contributed to the annual value of $648.5 million for FY2024, which is 9.57% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Total Non-Current Liabilities stood at $654.3 million, which was down 1.31% from $663.0 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $682.4 million during Q1 2022, with a 5-year trough of $302.0 million in Q3 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Total Non-Current Liabilities value was $637.5 million (recorded in 2024), while the average stood at $615.9 million.
  • Data for Apellis Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY increase of 136.93% (in 2021) and a maximum YoY decrease of 32.73% (in 2021) over the last 5 years.
  • Over the past 5 years, Apellis Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $338.0 million in 2021, then skyrocketed by 86.60% to $563.5 million in 2022, then grew by 3.81% to $591.9 million in 2023, then grew by 9.57% to $648.5 million in 2024, then declined by 0.09% to $654.3 million in 2025.
  • Its Total Non-Current Liabilities was $654.3 million in Q3 2025, compared to $663.0 million in Q2 2025 and $641.0 million in Q1 2025.